This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Rheumatoid Arthritis
and you are
over 20
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The primary objective of this study is to evaluate the efficacy and safety of CDP6038 administered subcutaneous (sc) at various doses compared to placebo.

Provided treatments

  • Biological: Placebo
  • Biological: Olokizumab 60 mg
  • Biological: Olokizumab 120 mg
  • Biological: Olokizumab 240 mg

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01463059. The sponsor of the trial is UCB Japan Co. Ltd. and it is looking for 119 volunteers for the current phase.
Official trial title:
A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Asian Subjects With Active Rheumatoid Arthritis Having Previously Failed TNF Blocker Therapy